Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride

What Was Tested

Researchers studied Insulin Glargine and Insulin Aspart in this randomized controlled trial publication.

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Primary endpoint was the difference in absolute change in HbA (1c) between groups after 26 weeks of treatment.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Nothing was hidden in this open-label Insulin Glargine study: the patients and staff both knew the treatment.

Groups ran in parallel: each of the patients stayed in one arm throughout.

The timeline in the abstract includes 26 weeks.

What Was Measured

PubMed files the paper under topics including Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Glargine and Insulin Aspart in 2 patients over 26 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association), a journal based in Germany.

More context: the Insulin Glargine compound page and the Insulin Aspart compound page.